Redcare Pharmacy stock: Berenberg raises target to EUR 102.00
Published on 10/20/2026 at 17:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSReporting date October 29, 2026
- Berenberg raised its Redcare Pharmacy target from EUR 94.00 to EUR 102.00 on October 6, 2026.
- Redcare Pharmacy targets 16.00 to 18.00 percent revenue growth for fiscal year 2026.
- Redcare Pharmacy stock costs EUR 77.00 at Lang & Schwarz on October 20, 2026 at 5:01 p.m. CEST, 2.94 percent above the Xetra close of October 16, 2026.
Redcare Pharmacy (ISIN NL0012044747) drew a higher Berenberg target of EUR 102.00 from EUR 94.00 on October 6, 2026, while the Buy rating stayed unchanged, according to onvista. At Lang & Schwarz in trading on October 20, 2026 at 5:01 p.m. CEST, the stock was trading at EUR 77.00, up 2.94 percent versus the Xetra close of October 16, 2026 at EUR 74.80.
Target implies 32.47 percent upside
The Berenberg target stands 32.47 percent above the Lang & Schwarz price. The bank kept its Buy rating, and the analyst linked the higher valuation to prescription-drug activity and customer purchasing behavior, according to the October 6, 2026 study reported by onvista.
Price stays below the yearly high
Redcare Pharmacy traded between EUR 75.95 and EUR 77.90 on October 20, 2026, with 30,861 shares changing hands. Its 52-week range was EUR 30.20 to EUR 85.05, leaving the stock 9.47 percent below the high. The current price is 155.96 percent above the 52-week low.
What date comes next?
The company is scheduled to publish its third-quarter interim statement on October 29, 2026, and to hold its quarterly conference call the same day, according to FinancialFilings. The same release says fiscal-year 2026 revenue growth guidance rose to 16.00 to 18.00 percent from 15.00 to 17.00 percent, while adjusted EBITDA margin guidance stayed at 2.50 to 3.00 percent.
That guidance gives the October reporting date a clear measurement point: investors will be able to compare third-quarter prescription trends with the raised full-year range. German prescription revenue was guided to EUR 730.00 million to EUR 760.00 million for fiscal year 2026, versus EUR 680.00 million to EUR 720.00 million previously, according to FinancialFilings.
Valuation remains in focus
Redcare Pharmacy had a market capitalization of EUR 1.6 billion and a price-to-earnings ratio of minus 36.79 as of October 20, 2026. The company operates in healthcare distribution, while its investor-relations page describes more than 100,000 packages delivered per day and an adjusted EBITDA potential above 8.00 percent over the long term.
Global Banking & Finance Review identifies Redcare Pharmacy as RDC.DE on Xetra under ISIN NL0012044747 and places the company in the SDAX, according to its October 20, 2026 reference page.
Redcare Pharmacy at EUR 77.00
Redcare Pharmacy was trading at EUR 77.00 at Lang & Schwarz on October 20, 2026 at 5:01 p.m. CEST, up 2.94 percent versus the Xetra close of October 16, 2026 at EUR 74.80. Its 52-week high was EUR 85.05.
The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.
Redcare Pharmacy key facts
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- Ticker: RDC.DE
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 20, 2026, 5:01 p.m. CEST): EUR 77.00
- Change versus Xetra close: plus 2.94 percent
- Xetra close (October 16, 2026): EUR 74.80
- Market capitalization: EUR 1.6 billion (as of October 20, 2026)
- 52-week range: EUR 30.20-85.05 (as of October 20, 2026)
- Sector / Industry: Healthcare / Medical Distribution
- Index membership: SDAX
- Next earnings date: October 29, 2026
Market context: Market report DAX.
